Trial Profile
An open, parallel trial to study the effect of hepatic impairment on eluxadoline pharmacokinetics
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2017
Price :
$35
*
At a glance
- Drugs Eluxadoline (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacokinetics
- Sponsors Furiex Pharmaceuticals
- 18 Jul 2017 Results published in the Journal of Clinical Pharmacology
- 20 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics